Company Information
USD
21.12
- (0.6%)
NASDAQ:EXEL, EXELIXIS, INC.
Industry: Biotechnology
End of Day: 15 May 2024 GMT-4
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Address
1851 Harbor Bay Parkway
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Dr. Alan M. Garber, M.D.,PhD
Director
Dr. Mary C. Beckerle, PhD
Director
Dr. Sue Gail Eckhardt, M.D.
Director
Dr. George H. Poste, D.V.M.,F.R.S.,PhD
Director
Mr. Jack L. Wyszomierski, M.S.
Director
Dr. Michael M. Morrissey, PhD
CEO/Director/President
Dr. Stelios Papadopoulos,PhD
Chairman of the Board/Co-Founder/Director
Mr. David Johnson
Director
Dr. Maria C. Freire, PhD
Director
Ms. Julie Anne Smith
Director
Mr. Christopher J. Senner
CFO/Chief Accounting Officer/Executive VP
Ms. Jacqueline Wright
Director
Mr. Tomas J. Heyman
Director
Mr. Robert Oliver, M.B.A.
Director
Mr. Jeffrey J. Hessekiel
Executive VP/General Counsel/Secretary
Mr. Patrick J. Haley
Executive VP, Divisional
Dr. Dana T. Aftab, PhD
Chief Scientific Officer/Executive VP, Divisional
Ownership
Institution Holdings
BlackRock Inc
36,014,432 (11.878%)
Vanguard Group Inc
31,671,090 (10.446%)
Farallon Capital Management, L.L.C.
26,634,500 (8.785%)
BlackRock Fund Advisors
19,101,279 (6.300%)
Renaissance Technologies Corp
15,615,716 (5.150%)
State Street Corporation
13,032,818 (4.299%)
FMR LLC
13,050,178 (4.197%)
Vanguard Investments Australia Ltd
9,845,294 (3.247%)
JPMorgan Chase & Co
7,741,589 (2.553%)
SSGA Funds Management Inc
5,688,576 (1.876%)
Funds Holdings
Vanguard US Total Market Shares ETF
9,782,498 (3.226%)
Vanguard Total Stock Market Index Fund
9,782,498 (3.226%)
iShares Core S&P Mid-Cap ETF
9,466,712 (3.122%)
Vanguard Small Cap Index
7,941,521 (2.619%)
Vanguard Institutional Extnd Mkt Idx Tr
4,600,038 (1.517%)
Vanguard Small Cap Growth Index Fund
4,428,192 (1.461%)
SPDR® S&P Biotech ETF
3,832,024 (1.264%)
Vanguard Explorer Fund
2,741,348 (0.904%)
SPDR® S&P MIDCAP 400 ETF Trust
2,474,417 (0.816%)
Stephens SMID Select Growth
2,384,701 (0.787%)
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
